Company intelligence / Profile preview

Emglev Therapeutics

Paris, Île-de-France, Franceemglev-therapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Emglev Therapeutics developed a proprietary synthetic single-domain antibody platform as a spin-off from Institut Curie. The company demonstrated preclinical proof-of-concept for its technology with various formats including CAR-Ts and bispecific T-cell engagers. Its approach aims to overcome the limitations of conventional immunotherapies—especially for solid tumors—and has broad applicability across oncology, autoimmune, and inflammatory indications. The company was acquired by Valerio Therapeutics in September 2024 to accelerate development within the new subsidiary Valour Bio.

Therapeutic areas: OncologyImmunology
Modalities: Synthetic single-domain antibodies (sdAbs)Bispecific T-cell engagersCAR-T sdAb drugsDrug and radio-conjugates
Industry: Biotech

Beyond the preview

Go deeper on Emglev Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emglev Therapeutics.

Explore the full profile